Company & Sponsor Intelligence

Genzyme, a Sanofi Company

Evidence-linked intelligence derived from the current NeuroRisk clinical research corpus. Coverage reflects indexed source data and is not a claim of complete company activity.

Request enterprise analysis →

Indexed trials3

Recruiting0

Completed3

Countries1

Therapeutic footprint

multiple_sclerosisparkinsons

Indexed studies

NCT00548405Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study Two
multiple_sclerosis · United StatesPHASE3

NCT02201108Efficacy, Safety and Pharmacokinetics of Teriflunomide in Pediatric Patients With Relapsing Forms of Multiple Sclerosis
multiple_sclerosis · United StatesPHASE3

NCT00229736A Study of AAV-hAADC-2 in Subjects With Parkinson's Disease
parkinsons · United StatesPHASE1

Intelligence layer updated: 2026-10-16 06:15:38.640633+00:00

Enterprise intelligence

Compare sponsor activity, recruiting momentum, therapeutic exposure, geography and connected research signals across the neuroscience ecosystem.

Request comparative intelligence →